Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy;Prise intermittente de statines chez des patients ayant présenté une myopathie induite par les statines

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages 398-404

  Keating, Alyssa J ^a   Campbell, Kristen Bova ^a   Guyton, John R ^b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; HUMAN; MYOPATHY; PATIENT SAFETY; PRIORITY JOURNAL; RISK REDUCTION;

DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES;

EID: 84875200123     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R509     Document Type: Article

References (35)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. doi: 10.1001/jama.285.19.2486
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720-32. doi: 10.1016/j.jacc.2004.07.001
3. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68.
4. Vandenberg BF, Robinson J. Management of the patient with statin intolerance. Curr Atheroscler Rep 2010;12:48-57. doi: 10.1007/s11883-009-0077-8
5. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol 2012;159:169-76. doi: 10.1016/j.ijcard.2011.07.048
6. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 2003;37:274-8. doi: 10.1345/aph.1C314
7. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23:1663-7. doi: 10.1592/phco.23.15.1663.31953
8. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80. doi: 10.1592/phco.23.7.871.32720
9. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. doi: 10.1161/01.CIR.101.2.207
10. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14. doi: 10.1007/s10557-005-5686-z
11. Metz CA, Lucas KH. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother 2001;35:496-500. doi: 10.1345/aph.10164
12. Reindl EK, Wright BM, Wargo KA. Alternate-day statin therapy for the treatment of hyperlipidemia. Ann Pharmacother 2010;44:1459-70. doi: 10.1345/aph.1M571
13. Elis A, Lishner M. Non-every day statin administration-a literature review. Eur J Intern Med 2012;23:474-8. doi: 10.1016/j.ejim.2012.02.006
14. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83: 687-700. doi: 10.4065/83.6.687
15. Arca M, Pigna G, Favoccia C. Management of statin-intolerant patient. Panminerva Med 2012;54:105-18.
16. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010;12:322-30. doi: 10.1007/s11883-010-0120-9
17. Reinhart KM, Woods JA. Strategies to preserve the use of statins in patients with previous muscular adverse effects. Am J Health Syst Pharm 2012;69:291-300. doi: 10.2146/ajhp100700
18. Mackie BD, Satija S, Nell C, Miller J, Sperling LS. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to stain therapy. Am J Cardiol 2007;99:291. doi: 10.1016/j.amjcard.2006.07.093
19. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007;100:554-5. doi: 10.1016/j.amjcard.2007.03.059
20. Gopalagowda BH, Cutchins C, Cutchins DC, Peiris AN. Alternate day rosuvastatin, an underutilized option in statin intolerant hyperlipidemic patients: a case report and literature review. Tenn Med 2011;104:49-51.
21. Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103:393-4. doi: 10.1016/j.amjcard.2008.09.095
22. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747-8. doi: 10.1016/j.amjcard.2008.02.061
23. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6. doi: 10.1345/aph.1K604
24. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7. doi: 10.1016/j.jacc.2009.04.053
25. Product information. Crestor (rosuvastatin calcium). Wilmington, DE: AstraZeneca, Feb 2012.
26. Product information. Lipitor (atorvastatin calcium). New York, NY: Pfizer, Feb 2012.
27. Najib NM, Idkaidek N, Adel A, et al. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos 2003;24:183-9. doi: 10.1002/bdd.347
28. Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997;38: 1496-500.
29. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162:227-44. doi: 10.1016/S0021-9150(01)00709-2
30. Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012;28:371-8. doi: 10.1185/03007995.2012.657302
31. Reddy KJ, Singh M, Batsell RR, et al. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J Clin Hypertens (Greenwich) 2009;11:766-8. doi: 10.1111/j.1559-4572.2009.00055.x
32. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5. doi: 10.1016/j.amjcard.2007.09.096
33. Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol 2011;5:308-15. doi: 10.1016/j.jacl.2011.03.454
34. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6. doi: 10.1016/j.jacc.2005.04.064
35. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6. doi:10.1001/archinte.165.22.2671